INCYTE CORP. news, videos and press releases - Page 6
For more news please use our advanced search feature.
INCYTE CORP. - More news...
INCYTE CORP. - More news...
- Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
- Incyte to Present at Upcoming Investor Conference
- Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting
- Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
- More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
- Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers
- Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments
- Incyte to Report Third Quarter Financial Results
- Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
- Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
- Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
- Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community
- Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
- Incyte to Present at Upcoming Investor Conference
- National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
- Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
- FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints
- Incyte to Report Second Quarter Financial Results
- Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14
- Incyte Investor Conference Update
- Incyte Launches New Global Responsibility Section on Incyte.com
- Incyte to Present at Upcoming Investor Conferences
- Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
- Incyte to Present at Upcoming Investor Conference
- Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
- Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
- Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
- Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte to Present at Upcoming Investor Conference
